Optimal two-stage randomized phase II clinical trials

Area of Science:

• Clinical Trials
• Biostatistics
• Drug Development

Background:

• Randomized phase II trials efficiently evaluate multiple treatments before phase III studies.
• Selection designs lack minimal efficacy assessment and early stopping for futility.
• Classic Simon designs can be inefficient with large maximum sample sizes.

Purpose of the Study:

• To propose an adaptive two-stage randomized phase II clinical trial design.
• To improve efficiency and manage sample size adaptively based on treatment arm progression.
• To maintain desirable operating characteristics while reducing maximum planned sample size.

Main Methods:

• A novel two-stage randomized phase II design is presented.
• Sample size is adaptively adjusted in the second stage based on the number of arms advancing from the first stage.
• The design employs optimality criteria similar to Simon's single-arm studies.

Main Results:

• The proposed adaptive design maintains operating characteristics comparable to using multiple single-arm studies.
• It generally achieves a smaller actual sample size when most treatments demonstrate efficacy.
• This leads to significant efficiencies in the maximum planned sample size.

Conclusions:

• The adaptive two-stage design offers an efficient alternative for phase II clinical trials with multiple treatment arms.
• It balances the need for efficacy assessment with practical sample size considerations.
• This approach enhances the feasibility of early-phase drug development research.